Inicio>>Signaling Pathways>> Tyrosine Kinase>> c-MET>>Terevalefim

Terevalefim (Synonyms: ANG-3777)

Catalog No.GC63215

Terevalefim (ANG-3777), un mimético del factor de crecimiento de hepatocitos (HGF), activa selectivamente el receptor c-Met.

Products are for research use only. Not for human use. We do not sell to patients.

Terevalefim Chemical Structure

Cas No.: 1070881-42-3

Tamaño Precio Disponibilidad Cantidad
5 mg
135,00 $
Disponible
10 mg
243,00 $
Disponible
25 mg
486,00 $
Disponible
50 mg
810,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor[1][2].

Terevalefim (ANG-3777) (0-10 μM) significantly inhibited cancer cells proliferation in HUVECs[2].

Terevalefim (ANG-3777) decreases apoptosis, increases proliferation, and promotes organ repair and function in animal models[1].Terevalefim (ANG-3777, 40 mg/kg, IP) phosphorylates the c-Met receptor in rats[2].

[1]. Jonathan S Bromberg, et al. Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. Transplantation. 2021 Feb 1;105(2):443-450.
[2]. Latha Paka, et al. The Effect of ANG-3777 on Hepatocyte Growth Factor Receptor, c-MET Signaling. American Transplant Society.

Reseñas

Review for Terevalefim

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Terevalefim

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.